Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search


Neuren granted US patent for NNZ-2566

Neuren granted US patent for NNZ-2566

• US patent issued for second lead compound NNZ-2566
• Patent scope is broad and covers composition of matter, therapeutic uses and methods of administration of NNZ-2566
• NNZ-2566 is being co-developed by Neuren with the US Army’s Walter Reed Institute of Research in a traumatic brain injury program

Neuren Pharmaceuticals (ASX: NEU) is pleased to announce that its patent application entitled “GPE Analogs and Peptidomimetics” (PCT/US02/16361) has been issued in the United States (US Patent No: 7,041,314) on 9 May 2006. The patent describes Neuren’s second pipeline drug, NNZ-2566, a neuroprotective analogue of Glypromate®.

The US patent is extremely wide-ranging, covering the chemical composition of NNZ-2566 in all formulations as well as all uses of the compound and specifically claims all pharmaceutical compositions of NNZ-2566 including compositions for oral administration over a wide range of dosages and administration of NNZ-2566 via other routes.

The patent also specifically covers therapeutic applications of NNZ-2566 for the treatment of damage to the central nervous system.

Neuren now has the exclusive rights to make, sell and use NNZ-2566 in the US until 24 May 2022 (priority date 24 May 2001). The US patent gives Neuren a unique position to investigate and commercialise NNZ-2566 as a systemic neuroprotective treatment following acute insults to the central nervous system such as traumatic brain injury (TBI), stroke or oxygen deprivation of the brain associated with coronary artery bypass graft (CABG) surgery as well as chronic degenerative conditions of the central nervous system such as Alzheimer’s and Parkinson’s disease.

Neuren is currently co-developing NNZ-2566 as a treatment for TBI with the US Army’s Walter Reed Army Institute of Research (WRAIR). The issued US patent is the parent to the recent patent filing by Neuren based on the results of experiments by WRAIR showing a reduction in non-convulsive seizures after administration of NNZ-2566. Non-convulsive seizures are an important predictor of recovery following TBI. NNZ-2566 is currently undergoing a Phase 1 safety and pharmacokinetics trial.

In addition to therapeutic use of NNZ-2566 in acute indications, Neuren plans to develop NNZ-2566 as a protective therapeutic in a variety of chronic neurodegenerative diseases.

Each year in the US there are 400,000 CABG procedures, 800,000 strokes and 1.5 million TBI incidents.

About Neuren Pharmaceuticals

Neuren Pharmaceuticals (ASX: NEU) is a biotechnology company developing novel therapeutics in the fields of neurotherapy and metabolic disorders. The Neuren portfolio consists of six product families, targeting markets with large unmet needs and limited competition.

Neuren has two lead candidates, Glypromate® and NNZ-2566, targeting a range of acute and chronic neurological conditions. Neuren has commercial and development partnerships, including Pfizer, the US Army’s Walter Reed Army Institute of Research and Metabolic Pharmaceuticals.

For more information, please visit Neuren’s website at


© Scoop Media

Business Headlines | Sci-Tech Headlines


ScoopPro: Helping PR Professionals Get More Out Of Scoop has been a fixture of New Zealand’s news and Public Relations infrastructure for over 18 years. However, without the financial assistance of those using Scoop in a professional context in key sectors such as Public Relations and media, Scoop will not be able to continue this service... More>>

Insurance: 2017 Worst Year On Record For Weather-Related Losses

The Insurance Council of New Zealand (ICNZ) announced today that 2017 has been the most expensive year on record for weather-related losses, with a total insured-losses value of more than $242 million. More>>


Crown Accounts: Govt Books In Line With Forecasts

The Government’s financial statements for the four months to 31 October indicate the books are tracking along with Treasury’s Budget forecasts, Finance Minister Grant Robertson says. More>>


Expert Reaction: Ross Sea Region Marine Protected Area In Force

Sweeping new protections for Antarctica's Ross Sea will come into effect on Friday 1 December. After five years of debate, the marine protected area (MPA) was agreed in 2016 after a joint proposal by New Zealand and the United States... More>>